Condition: Solid Tumors · Sarcomas · Sponsor: Zai Lab (Shanghai) Co., Ltd.
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
This description comes directly from the study's public registry record.
ZL-6201-001 Study Team · 650.360.1601 · ZL-6201-001@zailaboratory.com
Always discuss trial participation with your own doctor first.
| Zai Lab Site 02003 | Los Angeles, California, United States | Recruiting |
| Zai Lab Site 02030 | New Haven, Connecticut, United States | Recruiting |
| Zai Lab Site 02026 | Sarasota, Florida, United States | Recruiting |
| Zai Lab Site 02005 | St Louis, Missouri, United States | Recruiting |
| Zai Lab Site 02002 | New York, New York, United States | Recruiting |
| Zai Lab Site 02006 | Fairfax, Virginia, United States | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07374848